EN DE
Watch BibbInstruments AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BibbInstruments AB (BIBB) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of BibbInstruments AB stock SEK 0.27, price SEK 0.35, that is 21.9% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE

BA BibbInstruments AB logo Thin data Nov 16, 2026

BibbInstruments AB

BIBB · ST

Expensive (fair value 22% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Fair value kr 0.2709 · Overvalued 
Quality 34/100 
Falling price (downtrend) 
Weak Growth 
Negative free cash flow 
Trails peers (2/7) 
Narrow moat 7/100
Thin data 
Estimate
Watch BibbInstruments AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 10.60 kr 0.3430 Fair Value kr 0.2709 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range kr 0.3430 – kr 10.60 · fair‑value band kr 0.2032 – kr 0.3386 · the kr 0.3470 price screens above the kr 0.2709 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow BibbInstruments in your weekly email

Every Wednesday you see whether BibbInstruments is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BiBBInstruments AB, a medical technology company, develops and markets electrically powered endoscopic biopsy systems in the United States and Europe.

Show moreShow less

The company offers EndoDrill which enables tissue sampling, with the aim of improving diagnostics in several common cancers, including those affecting the pancreas, stomach, liver, lungs, and urinary bladder.

It also provides EndoDrill GI which used for endoscopic ultrasound; EndoDrill EBUS is used in the airways during endobronchial ultrasound (EBUS); and EndoDrill URO that is used with a standard cystoscope for sampling of muscle-invasive bladder cancer.

The company was incorporated in 2013 and is headquartered in Lund, Sweden.

Stock analysis

BibbInstruments AB (BIBB) currently trades at kr 0.3470, while our estimate is kr 0.2709, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.2032 (bear) to kr 0.3386 (bull), the price of kr 0.3470 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

BibbInstruments AB reported revenue of 401K SEK in FY2025 versus 0 SEK in FY2022. Reported net income was −14.6M SEK in FY2025.

Key figures

Market cap 57.2M SEK (≈ $5.7M) Micro · P/S ratio 67.8 · EPS (TTM) kr −0.2600 · Return on equity −33.3% · Return on assets (EBIT) −35.1% (4-year average) · Operating margin −1,194% · Revenue (TTM) 947K SEK · Revenue growth (YoY) +192%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 7 out of 100 (medium confidence).

What moves the price

The share trades about 91% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −22%, BIBB screens richer than that median.

Fair Value

Bear kr 0.2032 Fair Value kr 0.2709 Bull kr 0.3386
Price kr 0.3470 · Downside -21.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 59
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 88
Debt, balance sheet and risk of trouble
Investment 49
Does it invest with discipline instead of growing at any price?
Low Volatility 15
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BIBB screens overvalued: fair value 22% below the price. Compare with Abbott Laboratories, →

Compare BibbInstruments AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −21.9% · Below median
Profitability
Return on assets −36.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 192.3% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.52× · Cheaper than median
P/S (12 months) 60.35× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
DexCom, Inc DXCM $81.61 $91.66 +12% vs BIBB
Boston Scientific Corporation BSX $43.69 $48.77 +12% vs BIBB
Stryker Corporation SYK $310.72 $340.60 +10% vs BIBB
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.30 ¥197.34 +7% vs BIBB
GE HealthCare Technologies Inc GEHC $82.96 $69.92 −16% vs BIBB
Siemens Healthineers AG SHL €44.00 €34.51 −22% vs BIBB
Edwards Lifesciences Corporation EW $107.11 $81.94 −24% vs BIBB
Medtronic plc MDT $102.88 $74.89 −27% vs BIBB
Abbott Laboratories, ABT $107.45 $75.28 −30% vs BIBB
Koninklijke Philips N.V PHIA €27.54 €15.23 −45% vs BIBB

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BibbInstruments AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BibbInstruments AB Fair Value". https://www.fairvalue-calculator.com/stock/BIBB

Frequently asked questions

Is BibbInstruments AB (BIBB) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is kr 0.2709 versus a price of kr 0.3470, about 22% lower (overvalued).
What is the fair value of BIBB?
Our estimate for BibbInstruments AB is kr 0.2709 (as of Nov 16, 2026), built from audited fundamentals. The current price: kr 0.3470.
What is the quality score of BIBB?
BibbInstruments AB has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BibbInstruments AB (BIBB)?
Our calculated price target is the estimate of kr 0.2709 (as of Nov 16, 2026). Cautious scenario kr 0.2032, optimistic scenario kr 0.3386. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the BibbInstruments AB stock forecast for 2026?
Our estimate puts fair value at kr 0.2709, about 22% lower versus a price of kr 0.3470 (overvalued). Cautious scenario kr 0.2032, optimistic scenario kr 0.3386. The calculation is refreshed regularly with new filings.
What is the revenue of BibbInstruments AB (BIBB)?
BibbInstruments AB reported trailing-twelve-month revenue of about 947K SEK (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of BibbInstruments AB (BIBB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BibbInstruments AB it is kr 0.2709 per share (as of Nov 16, 2026), against a price of kr 0.3470.
Is BibbInstruments AB stock overvalued or undervalued in 2026?
As of Nov 16, 2026, BIBB trades above its calculated fair value: price kr 0.3470, fair value kr 0.2709, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIBB?
No. The price is what the market pays today (kr 0.3470); the fair value is what the company's own numbers justify (kr 0.2709). For BibbInstruments AB the two are kr 0.0761 per share apart. That gap is exactly why we show both numbers side by side.
How much is BibbInstruments AB worth?
The market values BibbInstruments AB at about 57.2M SEK (market capitalisation, as of Nov 16, 2026). Per share that is kr 0.3470; our models calculate a fair value of kr 0.2709 per share.
What do the bullish and bearish scenarios say about BIBB?
Our models span a range for BibbInstruments AB: cautious scenario kr 0.2032, base kr 0.2709, optimistic kr 0.3386 per share (as of Nov 16, 2026, price kr 0.3470). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BibbInstruments AB (BIBB)?
Balance-sheet figures for BibbInstruments AB (as of Nov 16, 2026): return on equity −33.3%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is BIBB from its 52-week high?
BibbInstruments AB trades at kr 0.3470, about 91% below its 52-week high of kr 3.74 and 1% above the low of kr 0.3430 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.2709 is for.
Which stocks are comparable to BibbInstruments AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BibbInstruments AB stock attractive at the current price?
The data as of Nov 16, 2026: price kr 0.3470, calculated fair value kr 0.2709 (−22%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. BibbInstruments AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BibbInstruments AB (BIBB)?
The closing price on Nov 16, 2026 was kr 0.3470. Our estimate is kr 0.2709, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BibbInstruments AB right now?
The price sits above even our optimistic bull case (kr 0.3386). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of BibbInstruments AB

How large is the market capitalisation of BibbInstruments AB (BIBB)?
The market capitalisation of BibbInstruments AB is 57.2M SEK (≈ $5.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BibbInstruments AB (BIBB)?
The price-to-sales ratio of BibbInstruments AB is 67.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BibbInstruments AB (BIBB)?
Earnings per share at BibbInstruments AB are kr −0.2600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BibbInstruments AB (BIBB)?
The return on equity (ROE) of BibbInstruments AB is −33.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BibbInstruments AB (BIBB)?
On an EBIT basis the return on assets of BibbInstruments AB is −35.1% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BibbInstruments AB (BIBB)?
The operating margin of BibbInstruments AB is −1,194% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BibbInstruments AB (BIBB)?
Revenue at BibbInstruments AB is growing 192% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BibbInstruments AB (BIBB) generate?
The free cash flow of BibbInstruments AB is −18.1M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch BibbInstruments AB in the live analysis

One click puts BibbInstruments AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.